Freeze and unleash: experimental combo aims to boost immune attack on aggressive breast cancer

NCT ID NCT05806385

Not yet recruiting Disease control Sponsor: Texas Tech University Health Sciences Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This early-stage trial tests whether freezing a breast tumor (cryoablation) before giving an immunotherapy drug (PD1 inhibitor) can help the immune system better recognize and attack triple-negative breast cancer. About 36 women with early-stage, high-risk breast cancer will receive the combination before standard chemotherapy. The goal is to see if this approach increases the chance of eliminating all cancer cells by the time of surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PD1 inhibitor (a type of immunotherapy) combined with cryoablation
What this could lead to: If it works, this combination could improve how well the immune system attacks triple-negative breast cancer, potentially leading to better tumor clearance and fewer recurrences.
What could go wrong: This is a very early (Phase 1/2) trial with only 36 participants, so results may not apply broadly. The combination could cause immune-related side effects or fail to improve outcomes over standard treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TRIPLE NEGATIVE BREAST CANCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.